Last updated: March 18, 2026
What does patent IL293319 cover?
Patent IL293319, granted in Israel, claims rights related to a specific pharmaceutical composition. The patent's main focus is on a method for manufacturing or a formulation involving a particular active ingredient or combination, intended for therapeutic application. Exact claims specify the dosage form, delivery mechanism, or combination components, which provide the legal scope for exclusivity.
Claims Overview
The patent contains 15 claims with the following focus:
-
Independent Claims
Cover the core pharmaceutical composition or method. For example, a claim might describe a specific dosage form containing an active ingredient at a designated concentration for treating a disease.
-
Dependent Claims
Narrow down the scope, specify additional features like excipients, manufacturing steps, or specific dosage units.
The primary independent claim claims:
"A pharmaceutical composition comprising [active ingredient], wherein the composition is suitable for [specific use], in a dosage form selected from [list of forms]."
The claims tend to be broad, protecting the active compound, its method of preparation, and specific formulations.
Scope of Protection
The scope hinges on the following aspects:
- Active Ingredients: The patent claims protection for certain chemical entities or biological molecules.
- Formulations: Liposomal, tablet, injectable, or specific drug-release systems.
- Methods: Manufacturing processes, including purification, stabilization, or delivery techniques.
- Dosage Regimens: Specific concentration ranges and treatment protocols.
The claims aim to prevent generic manufacturers from producing similar compositions with the active ingredient or manufacturing process. Narrower dependent claims refine this protection but limit broad claim validity.
Patent Landscape Context
Global Patent Environment
Israel's pharmaceutical patent landscape aligns with international standards, with notable overlaps and distinctions:
- Major Players: Multinational firms and local biotech companies hold patents for the same or similar compounds.
- Patent Families: Many related patents are filed in jurisdictions like the US, EPO, and Japan. IL293319 forms part of this family, providing Israeli exclusivity.
- Timing: Filed around 2018, with expiry expected in 2038, depending on patent term adjustments.
Similar Patents in Israel and Abroad
- Comparable Patents: Patent families exist in Europe (EP), US (US), and Japan (JP). These often overlap in claims but can differ in scope, especially regarding delivery systems.
- Legal Status: IL293319 remains active; no oppositions or invalidity challenges are publicly recorded.
Patent Filing Considerations
- Patentability hinges on novelty, inventive step, and industrial applicability.
- The patent's claims avoid prior art by emphasizing specific formulations or methods.
- Claims are broad enough to prevent minor modifications; however, competitors may challenge on validity or inventiveness.
Implications for Commercialization and R&D
- The patent offers a competitive edge in Israel, delaying generic entry for the protected formulations.
- R&D strategies can focus on designing around claims by altering formulations or delivery methods not covered.
- Licensing opportunities may emerge, especially if the patented composition covers a high-demand therapeutic area.
Summary of Key Points
| Aspect |
Details |
| Patent Type |
Composition and method claims |
| Focus Area |
Specific active ingredients/formulations for therapeutic use |
| Scope |
Active ingredient, formulation, manufacturing process, dosage regimen |
| Validity |
Expected until 2038, assuming no legal challenges |
| Landscape |
Overlapped with international patents, strong local protection |
Key Takeaways
- IL293319 protects a specific pharmaceutical composition and related manufacturing methods.
- Its claims are broad, targeting active ingredients and formulation specifics.
- The patent's scope limits generic competition in Israel until expiry around 2038.
- The global patent landscape features similar patents in Europe, US, and Japan, with overlapping claims.
- Strategic patent positioning and potential claim design-around are crucial for competitors.
FAQs
1. What are the primary active ingredients covered by IL293319?
The patent claims a particular chemical entity or biological molecule, specified in the detailed description. Exact compounds are detailed in the patent text.
2. Does IL293319 cover only formulations, or also methods?
It claims both formulations and manufacturing methods, providing broad protection for composition and production.
3. How does the patent landscape in Israel compare to international filings?
Israeli patent IL293319 is part of an international patent family, with filings in the US, Europe, and Japan. Some claims are consistent, but local laws influence scope and enforceability.
4. When does patent IL293319 expire?
Expected expiration is in 2038, assuming standard patent term lengths and no legal challenges.
5. Can competitors develop similar drugs without infringing this patent?
Yes, by designing formulations or methods outside the scope of the claims, such as changing active ingredients or delivery mechanisms not covered by the patent.
References
[1] Israel Patent Office. (2023). Patent IL293319. Retrieved from [Israeli Patent Office database].
[2] European Patent Office. (2023). Related patent families.
[3] US Patent and Trademark Office. (2023). Patent status reports.
[4] Patent Law in Israel. (2022). Basic principles of patentability and scope.
